NASDAQ · Biotechnology

OCGN (OCGN) Stock

$1.33 +0.00% NASDAQ: OCGN Healthcare

Valuation

MetricValue
Price$1.33
Market Cap$451.02M
P/E Ratio-6.48
P/B Ratio83.35
P/S Ratio114.48
EPS (TTM)$-0.23
52-Week High$2.73
52-Week Low$0.90
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE566.67%
ROA-125.95%
ROCE-183.04%
Gross Margin-1575.00%
Operating Margin-1575.00%
Net Margin-16.05%
Debt/Equity5.74
Current Ratio1.04

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$2.0M$6.0M$4.0M$4.0M
Operating Profit$-58.0M$-89.0M$-66.0M$-55.0M$-63.0M
Net Profit$-58.0M$-87.0M$-63.0M$-54.0M$-68.0M
EPS$-0.30$-0.40$-0.26$-0.20$-0.23
Op Margin—-3580.0%-1085.7%-1350.4%-1425.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$106.0M$109.0M$65.0M$82.0M$44.0M
Total Liabilities$10.0M$35.0M$24.0M$53.0M$56.0M
Cash$95.0M$78.0M$39.0M$59.0M$19.0M
Borrowings$3.0M$6.0M$7.0M$33.0M$33.0M

Latest News

Ocugen Signs Term Sheet to License Retinitis Pigmentosa Gene Therapy to Roots Pharmaceutical, Al-Dhow in MENA Region MT Newswires · Jul 13, 2026 Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa GlobeNewswire · Jul 13, 2026 Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances MarketBeat · Jul 11, 2026 Ocugen to Participate in Upcoming July Industry Conferences GlobeNewswire · Jul 1, 2026 Ocugen (OCGN) Stock Draws Fresh Price Target Split After Cautious Analyst View Simply Wall St. · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-48.0M$-60.0M$-62.0M$-42.0M$-57.0M
Investing Cash Flow$-3.0M$-21.0M$-7.0M$-7.0M$0
Financing Cash Flow$-9.0M$-1.0M$0$-4.0M$0
Net Cash Flow$71.0M$-18.0M$-38.0M$19.0M$-40.0M
Free Cash Flow$-49.0M$-65.0M$-73.0M$-46.0M$-57.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.35
EV / EBITDA-7.99
FCF Yield-11.65%
Quick Ratio1.86
Interest Coverage-13.19
Return 1Y8.55%
Return 3Y125.58%
Return 5Y-77.52%

Ownership

Insiders Held1.68%
Institutions Held34.57%
Institutions Float Held35.16%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC13,804,1112026-03-31
Millennium Management Llc13,727,1922026-03-31
State Street Corporation9,670,1912026-03-31
Marshall Wace LLP8,052,3502026-03-31
Blackrock Inc.7,304,9792026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPL $325.13 +2.61% 35.78 $4.78T 0.34%
MSFT $501.02 -1.24% 27.58 $3.72T 0.73%
GOOGL $335.02 -1.28% 16.98 $4.05T 0.26%
AMZN $254.92 -1.87% 20.66 $2.74T 0.00%
META $578.54 +1.08% 21.41 $1.47T 0.36%

About OCGN

OCGN is led by CEO Shankar Musunuri, publicly traded since 2014.

OCGN stock trades at $1.33 with a market capitalization of $451.02M. The stock is valued at a price-to-earnings (P/E) ratio of -6.48, price-to-book of 83.35, price-to-sales of 114.48. Over the past 52 weeks the stock has ranged between $0.90 and $2.73, and currently trades 51.2% below its 52-week high.

On profitability, OCGN generates a return on equity (ROE) of 566.67% — well above the market average, a sign of a high-quality business, return on capital employed of -183.04%, an operating margin of -1575.00%, a net profit margin of -16.05%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides